AU2004224053B2 - Oestrogen derivatives as inhibitors of steroid sulphatase - Google Patents

Oestrogen derivatives as inhibitors of steroid sulphatase Download PDF

Info

Publication number
AU2004224053B2
AU2004224053B2 AU2004224053A AU2004224053A AU2004224053B2 AU 2004224053 B2 AU2004224053 B2 AU 2004224053B2 AU 2004224053 A AU2004224053 A AU 2004224053A AU 2004224053 A AU2004224053 A AU 2004224053A AU 2004224053 B2 AU2004224053 B2 AU 2004224053B2
Authority
AU
Australia
Prior art keywords
group
alkyl
arh
compound
groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004224053A
Other languages
English (en)
Other versions
AU2004224053A1 (en
Inventor
Surinder Kumar Chander
Fabrice Jourdan
Mathew Leese
Simon Paul Newman
Barry Victor Lloyd Potter
Atul Purohit
Michael John Reed
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sterix Ltd
Original Assignee
Sterix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0306717A external-priority patent/GB0306717D0/en
Priority claimed from GB0315885A external-priority patent/GB0315885D0/en
Application filed by Sterix Ltd filed Critical Sterix Ltd
Publication of AU2004224053A1 publication Critical patent/AU2004224053A1/en
Application granted granted Critical
Publication of AU2004224053B2 publication Critical patent/AU2004224053B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
AU2004224053A 2003-03-24 2004-02-20 Oestrogen derivatives as inhibitors of steroid sulphatase Ceased AU2004224053B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0306717.0 2003-03-24
GB0306717A GB0306717D0 (en) 2003-03-24 2003-03-24 Compound
GB0315885.4 2003-07-07
GB0315885A GB0315885D0 (en) 2003-07-07 2003-07-07 Compound
PCT/GB2004/000705 WO2004085459A1 (en) 2003-03-24 2004-02-20 Oestrogen derivatives as inhibitors of steroid sulphatase

Publications (2)

Publication Number Publication Date
AU2004224053A1 AU2004224053A1 (en) 2004-10-07
AU2004224053B2 true AU2004224053B2 (en) 2011-06-09

Family

ID=33099976

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004224053A Ceased AU2004224053B2 (en) 2003-03-24 2004-02-20 Oestrogen derivatives as inhibitors of steroid sulphatase

Country Status (14)

Country Link
US (1) US7893284B2 (https=)
EP (1) EP1608671B1 (https=)
JP (1) JP4719144B2 (https=)
AT (1) ATE454395T1 (https=)
AU (1) AU2004224053B2 (https=)
BR (1) BRPI0408703A (https=)
CA (1) CA2520142C (https=)
DE (1) DE602004024966D1 (https=)
DK (1) DK1608671T3 (https=)
EA (1) EA011123B1 (https=)
ES (1) ES2339450T3 (https=)
MX (1) MXPA05010339A (https=)
PL (1) PL378577A1 (https=)
WO (1) WO2004085459A1 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0113920D0 (en) 2001-06-07 2001-08-01 Sterix Ltd Composition
US8030298B2 (en) 2005-05-26 2011-10-04 Abbott Products Gmbh 17β-HSD1 and STS inhibitors
US8288367B2 (en) 2006-11-30 2012-10-16 Solvay Pharmaceuticals Gmbh Substituted estratriene derivatives as 17BETA HSD inhibitors
WO2008090517A2 (en) * 2007-01-26 2008-07-31 Piramal Life Sciences Limited Enriched plant extract, compound, and methods for the treatment of proliferative disorders
EP2149371A1 (en) 2008-07-28 2010-02-03 PregLem S.A. Use of steroid sulfatase inhibitors for the treatment of preterm labor
EP2334686B1 (en) 2008-08-28 2019-02-27 President and Fellows of Harvard College Cortistatin analogues and syntheses therof
WO2010123545A2 (en) * 2009-04-22 2010-10-28 President And Fellows Of Harvard College Angiogenesis inhibitors
WO2012116290A2 (en) * 2011-02-25 2012-08-30 Washington University Neuroactive 17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
CN119192266A (zh) 2011-10-14 2024-12-27 萨奇治疗股份有限公司 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途
MX365644B (es) 2012-12-18 2019-06-10 Univ Washington Esteroides neuroactivos sustituidos con 19-alcoxi-17, profarmacos de los mismos, y metodos de tratamiento usando los mismos.
US9512170B2 (en) 2013-03-01 2016-12-06 Washington University Neuroactive 13, 17-substituted steroids as modulators for GABA type-A receptors
US9365502B2 (en) 2013-03-11 2016-06-14 Washington University Neuroactive substituted cyclopenta[b]phenanthrenes as modulators for GABA type-A receptors
US9562026B2 (en) 2013-03-14 2017-02-07 Washington University Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors
WO2014169836A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
WO2014169831A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
ES2807264T3 (es) 2013-04-17 2021-02-22 Sage Therapeutics Inc Esteroides neuroactivos 19-nor para métodos de tratamiento
JP6470258B2 (ja) 2013-04-17 2019-02-13 セージ セラピューティクス， インコーポレイテッド １９−ノルｃ３，３−ジ置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法
WO2015010054A2 (en) 2013-07-19 2015-01-22 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
ES2848823T3 (es) 2013-08-23 2021-08-12 Sage Therapeutics Inc Esteroides neuroactivos, composiciones y usos de los mismos
SG11201605178WA (en) 2013-12-24 2016-07-28 Harvard College Cortistatin analogues and syntheses and uses thereof
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10577390B2 (en) 2014-10-16 2020-03-03 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
ME03809B (me) 2014-10-16 2021-04-20 Sage Therapeutics Inc KOMPOZICIJE I POSTUPCI ZA LEČENJE POREMEĆAJA CNS-a
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
WO2016123056A1 (en) 2015-01-26 2016-08-04 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
EP4155314A1 (en) 2015-02-20 2023-03-29 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
WO2016182932A1 (en) 2015-05-08 2016-11-17 President And Fellows Of Harvard College Cortistatin analogues, syntheses, and uses thereof
WO2017004411A1 (en) 2015-07-01 2017-01-05 President And Fellows Of Harvard College Cortistatin analogues and syntheses and uses thereof
AU2017283878A1 (en) * 2016-06-15 2019-01-03 Sony Corporation Information processing device, observation system, observation method, and program
MA45599A (fr) 2016-07-11 2019-05-15 Sage Therapeutics Inc Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation
US20190233465A1 (en) 2016-07-11 2019-08-01 Sage Therapeutics, Inc. C7, c12, and c16 substituted neuroactive steroids and their methods of use
CR20240234A (es) 2019-05-31 2024-07-09 Sage Therapeutics Inc ESTEROIDES NEUROACTIVOS Y COMPOSICIONES DE ESTOS (Divisional 2021-629)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999033858A2 (en) * 1997-12-24 1999-07-08 Sri International Estrone sulfamate inhibitors of estrone sulfatase, and associated pharmaceutical compositions and methods of use
WO1999064013A1 (en) * 1998-06-10 1999-12-16 Sterix Limited Pharmaceutical composition with tumor necrosis factor a and 2-methoxyestrone-3-o-sulphamate for inhibition of estrone sulphatase
EP1284272A1 (en) * 2000-04-24 2003-02-19 Kyowa Hakko Kogyo Co., Ltd. Estra-1,3,5(10)-triene derivatives

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994439A (en) * 1989-01-19 1991-02-19 California Biotechnology Inc. Transmembrane formulations for drug administration
DE19723794A1 (de) * 1997-06-06 1998-12-10 Jenapharm Gmbh Nichtestrogene Derivate des Estradiols mit antioxidativer Aktivität
US6288050B1 (en) * 1997-07-18 2001-09-11 Duquesne University Of The Holy Ghost Steroid sulfatase inhibitors and methods for making and using the same
GB2331987B (en) * 1997-12-04 2002-11-27 Imperial College Polycyclic sulphamate inhibitors of oestrone sulphatase
AU783910B2 (en) * 1999-04-30 2005-12-22 Sterix Limited Use of estrone derivatives as antitumour agents
CN100338088C (zh) * 2000-05-11 2007-09-19 医学与化学研究所 2－取代的孕－1,3,5(10)－三烯和胆－1,3,5(10)－三烯衍生物及其生物活性
GB0020498D0 (en) * 2000-08-18 2000-10-11 Sterix Ltd Compound
WO2002016395A1 (en) * 2000-08-18 2002-02-28 The Board Of Trustees Of The University Of Illinois Prodrugs of betulinic acid derivatives for the treatment of cancer and hiv
WO2002062347A1 (en) 2001-02-05 2002-08-15 Oncology Sciences Corporation Method and composition of novel compounds for the therapy and targeting of the primary modalities of cancer cell proliferation and homeostasis
GB0421106D0 (en) * 2004-09-22 2004-10-27 Sterix Ltd Compound

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999033858A2 (en) * 1997-12-24 1999-07-08 Sri International Estrone sulfamate inhibitors of estrone sulfatase, and associated pharmaceutical compositions and methods of use
WO1999064013A1 (en) * 1998-06-10 1999-12-16 Sterix Limited Pharmaceutical composition with tumor necrosis factor a and 2-methoxyestrone-3-o-sulphamate for inhibition of estrone sulphatase
EP1284272A1 (en) * 2000-04-24 2003-02-19 Kyowa Hakko Kogyo Co., Ltd. Estra-1,3,5(10)-triene derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BOIVIN, R.P. et al., Journal of Medicinal Chemistry, 2000, vol. 43, pages 4465-4478 *

Also Published As

Publication number Publication date
JP2006521335A (ja) 2006-09-21
US7893284B2 (en) 2011-02-22
US20060094696A1 (en) 2006-05-04
EP1608671A1 (en) 2005-12-28
ES2339450T3 (es) 2010-05-20
DE602004024966D1 (de) 2010-02-25
EA200501426A1 (ru) 2006-06-30
DK1608671T3 (da) 2010-05-10
CA2520142C (en) 2011-01-04
BRPI0408703A (pt) 2006-03-07
CA2520142A1 (en) 2004-10-07
EA011123B1 (ru) 2008-12-30
AU2004224053A1 (en) 2004-10-07
HK1082258A1 (en) 2006-06-02
JP4719144B2 (ja) 2011-07-06
EP1608671B1 (en) 2010-01-06
PL378577A1 (pl) 2006-05-02
MXPA05010339A (es) 2005-12-14
WO2004085459A1 (en) 2004-10-07
ATE454395T1 (de) 2010-01-15

Similar Documents

Publication Publication Date Title
AU2004224053B2 (en) Oestrogen derivatives as inhibitors of steroid sulphatase
CA2519956C (en) Compound
JP4958377B2 (ja) ステロイドスルファターゼのインヒビターとしてのエストロゲン−１７−スルファメート
US20040009959A1 (en) Thioether sulphamate steroids as steroid inhibtors and anti-cancer compounds
US20070225256A1 (en) Compound
EP1996604A1 (en) Steroidal compounds as steroid sulphatase inhibitors
JP4931312B2 (ja) ステロイドスルファターゼのインヒビターとしてのハロゲン化スルファメート−、ホスホネート−、チオホスホネート−、スルホネート−、およびスルホンアミド−化合物
JP2003519658A (ja) ステロイド構造を含む薬学的組成物およびそれらの使用
JP4553586B2 (ja) ステロイドスルファターゼを阻害するための、ステロイド化合物
HK1082258B (en) Oestrogen derivatives as inhibitors of steroid sulphatase

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND CO-INVENTOR NAME FROM PUROHIT, ALAN TO PUROHIT, ATUL

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired